{
    "nct_id": "NCT00679341",
    "official_title": "A Randomized, Multicenter, Phase ii Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast with locally advanced or metastatic disease, and a candidate for chemotherapy.\n* Human epidermal growth factor receptor 2 (HER2)-positive.\n* No prior chemotherapy for their metastatic breast cancer (MBC).\n* Measurable disease.\n* Age ≥ 18 years.\n* For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception or 2 effective forms of non-hormonal contraception by the patient and/or partner. Contraception use must continue for the duration of study treatment and for at least 6 months after the last dose of study treatment. Male patients whose partners are pregnant should use condoms for the duration of the study.\n\nExclusion Criteria:\n\n* History of any chemotherapy for MBC.\n* An interval of \\< 6 months from the completion of cytotoxic chemotherapy in the neo-adjuvant or adjuvant setting until the time of metastatic diagnosis.\n* Trastuzumab ≤ 21 days prior to randomization.\n* Hormone therapy \\< 7 days prior to randomization.\n* Current peripheral neuropathy of Grade ≥ 3.\n* History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those previously mentioned.\n* Previous radiotherapy for the treatment of unresectable, locally advanced or metastatic breast cancer is not allowed if more than 25% of marrow-bearing bone has been irradiated or the last fraction of radiotherapy has been administered within approximately 3 weeks prior to randomization.\n* Brain metastases that are untreated, symptomatic, or require therapy to control symptoms or any radiation, surgery, or other therapy to control symptoms from brain metastases within 2 months prior to randomization.\n* History of exposure to the following cumulative doses of anthracyclines: Doxorubicin or liposomal doxorubicin \\> 500 mg/m\\^2; epirubicin \\> 900 mg/m\\^2; mitoxantrone \\> 120mg/m\\^2 and idarubicin \\> 90 mg/m\\^2.\n* Current unstable angina.\n* History of symptomatic congestive heart failure, or ventricular arrhythmia requiring treatment.\n* History of myocardial infarction within 6 months prior to randomization.\n* Left ventricular ejection fraction (LVEF) below 50% within approximately 28 days prior to randomization.\n* History of decreased LVEF or symptomatic congestive heart failure (CHF) with previous adjuvant trastuzumab treatment.\n* Cardiac troponin I ≥ 0.2 ng/mL within 28 days of randomization.\n* Severe dyspnea at rest because of complications of advanced malignancy or requiring current continuous oxygen therapy.\n* Current severe, uncontrolled systemic disease (eg, clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures).\n* Major surgical procedure or significant traumatic injury within approximately 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment.\n* Current pregnancy or lactation.\n* History of receiving any investigational treatment within approximately 28 days prior to randomization.\n* Current known infection with human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C virus.\n* History of intolerance (including Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab, murine proteins, or docetaxel.\n* Known hypersensitivity to any of the study drugs, including the excipients, or any drugs formulated in polysorbate 80.\n* Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.\n\nsex: ALL\n\nminimumAge: 18 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "* Histologically or cytologically confirmed adenocarcinoma of the breast with locally advanced or metastatic disease, and a candidate for chemotherapy.\n* Human epidermal growth factor receptor 2 (HER2)-positive.\n* No prior chemotherapy for their metastatic breast cancer (MBC).\n* Measurable disease.\n* Age ≥ 18 years.\n* For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception or 2 effective forms of non-hormonal contraception by the patient and/or partner. Contraception use must continue for the duration of study treatment and for at least 6 months after the last dose of study treatment. Male patients whose partners are pregnant should use condoms for the duration of the study.",
        "exclusion": "* History of any chemotherapy for MBC.\n* An interval of < 6 months from the completion of cytotoxic chemotherapy in the neo-adjuvant or adjuvant setting until the time of metastatic diagnosis.\n* Trastuzumab ≤ 21 days prior to randomization.\n* Hormone therapy < 7 days prior to randomization.\n* Current peripheral neuropathy of Grade ≥ 3.\n* History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those previously mentioned.\n* Previous radiotherapy for the treatment of unresectable, locally advanced or metastatic breast cancer is not allowed if more than 25% of marrow-bearing bone has been irradiated or the last fraction of radiotherapy has been administered within approximately 3 weeks prior to randomization.\n* Brain metastases that are untreated, symptomatic, or require therapy to control symptoms or any radiation, surgery, or other therapy to control symptoms from brain metastases within 2 months prior to randomization.\n* History of exposure to the following cumulative doses of anthracyclines: Doxorubicin or liposomal doxorubicin > 500 mg/m^2; epirubicin > 900 mg/m^2; mitoxantrone > 120mg/m^2 and idarubicin > 90 mg/m^2.\n* Current unstable angina.\n* History of symptomatic congestive heart failure, or ventricular arrhythmia requiring treatment.\n* History of myocardial infarction within 6 months prior to randomization.\n* Left ventricular ejection fraction (LVEF) below 50% within approximately 28 days prior to randomization.\n* History of decreased LVEF or symptomatic congestive heart failure (CHF) with previous adjuvant trastuzumab treatment.\n* Cardiac troponin I ≥ 0.2 ng/mL within 28 days of randomization.\n* Severe dyspnea at rest because of complications of advanced malignancy or requiring current continuous oxygen therapy.\n* Current severe, uncontrolled systemic disease (eg, clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures).\n* Major surgical procedure or significant traumatic injury within approximately 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment.\n* Current pregnancy or lactation.\n* History of receiving any investigational treatment within approximately 28 days prior to randomization.\n* Current known infection with human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C virus.\n* History of intolerance (including Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab, murine proteins, or docetaxel.\n* Known hypersensitivity to any of the study drugs, including the excipients, or any drugs formulated in polysorbate 80.\n* Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol."
    }
}